AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29950475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 29950480 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal computerised decision support system (CDSS) integrated in the electronic health record (EHR)
Number of subjects: 24
Study 29950480 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care antimicrobial stewardship (AMS)
Number of subjects: 24
Study 29950693 — intervention group
Group type: EXPERIMENTAL
Intervention: Total CK18 (tCK18)
Number of subjects: 109
Study 29950693 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptotic CK18 fragments (CK18F)
Number of subjects: 109
Study 29951525 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Apical (RVA) pacing
Number of subjects: 437
Study 29951525 — intervention group
Group type: COMPARATOR
Intervention: Non-RVA pacing
Number of subjects: 437
Study 29951599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scissors
Number of subjects: 1329
Study 29951599 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemostasis
Number of subjects: 1329
Study 29951631 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS for 20 min during training
Number of subjects: 40
Study 29951631 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 20 min during training
Number of subjects: 40
Study 29951634 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 200
Study 29951634 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 29951694 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (48-h continuous intravenous infusion)
Number of subjects: 0
Study 29951694 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher belinostat drug exposure
Number of subjects: 0
Study 29951694 — intervention group
Group type: EXPERIMENTAL
Intervention: q3week schedule of belinostat infusion
Number of subjects: 0
Study 29951750 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted individualized pneumoperitoneum strategy (ventilation with low tidal volume, modified lithotomy position, deep neuromuscular blockade, pre-stretching of the abdominal wall, individualized intra-abdominal pressure titration)
Number of subjects: 92
Study 29951750 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted individualized pneumoperitoneum strategy
Number of subjects: 92
Study 29951977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (stepwise dose escalation from 75 mg to 600 mg daily)
Number of subjects: 27
Study 29951977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study 29952243 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29952802 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear-mediated platelet activation (SMPA) quantified via the Platelet Activity State (PAS) assay before and after pump exchange and heart transplantation.
Number of subjects: 1
Study 29952895 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation (n = 11)
Number of subjects: 30
Study 29952895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment (n = 6)
Number of subjects: 30
Study 29952895 — intervention group
Group type: COMPARATOR
Intervention: Surgical randomization (n = 13)
Number of subjects: 30
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle co-activation during stair ascent
Number of subjects: 77
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle combinations within the same activity
Number of subjects: 77
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of muscle co-activation between activities
Number of subjects: 77
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral muscle co-activation
Number of subjects: 77
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle co-activation strategies during activities of daily living
Number of subjects: 77
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle co-activation during challenging activities
Number of subjects: 77
Study 29953745 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of mediolateral vs hamstrings/quadriceps co-activation
Number of subjects: 77
Study 29954008 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel classification system using peroral cholangioscopy (POCS) for bile duct lesions
Number of subjects: 171
Study 29954008 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert observers
Number of subjects: 171
Study 29954008 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-expert observers
Number of subjects: 171
Study 29954415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and rituximab maintenance therapy
Number of subjects: 23
Study 29954418 — intervention group
Group type: EXPERIMENTAL
Intervention: search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment
Number of subjects: 138
Study 29954418 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous suppression (CS) strategy, a repeated chronic topical antibiotic treatment
Number of subjects: 138
Study 29954418 — intervention group
Group type: COMPARATOR
Intervention: search and destroy (SD) strategy
Number of subjects: 138
Study 29954418 — intervention group
Group type: COMPARATOR
Intervention: continuous suppression (CS) strategy
Number of subjects: 138
Study 29954605 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 0
Study 29954605 — intervention group
Group type: COMPARATOR
Intervention: Immediate clamping
Number of subjects: 0
Study 29954728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogenic Shock team intervention (early multidisciplinary team activation, rapid initiation of mechanical circulatory support, hemodynamic-guided management)
Number of subjects: 250
Study 29954728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogenic Shock team intervention
Number of subjects: 250
Study 29954728 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (2015 and 2016)
Number of subjects: 250
Study 29954744 — intervention group
Group type: EXPERIMENTAL
Intervention: MINOCA
Number of subjects: 2690
Study 29954744 — intervention group
Group type: COMPARATOR
Intervention: MI-CAD
Number of subjects: 2690
Study 29954840 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 157
Study 29954840 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional experiments in GBC cell lines
Number of subjects: 157
Study 29954877 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost sexual health prevention strategies such as condoms
Number of subjects: 21
Study 29954877 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to eroticise male and female condoms
Number of subjects: 21
Study 29954932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib-melphalan-prednisone regimen (ixazomib 4.0 mg [days 1, 8, 15] plus melphalan-prednisone 60 mg/m)
Number of subjects: 61
Study 29954932 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ixazomib maintenance
Number of subjects: 61
Study 29955380 — intervention group
Group type: COMPARATOR
Intervention: TCZ-intravenous
Number of subjects: 3
Study 29955380 — intervention group
Group type: COMPARATOR
Intervention: TCZ-subcutaneous
Number of subjects: 3
Study 29955381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab monotherapy
Number of subjects: 140
Study 29955381 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate use
Number of subjects: 140
Study 29955680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention Program for Improving Nutritional Quality of Food Purchases
Number of subjects: 0
Study 29955682 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary legume foods, specific types not mentioned, duration not specified.
Number of subjects: 0
Study 29955692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad Libitum Carbohydrate and Fat Intake
Number of subjects: 0
Study 29955695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Number of subjects: 0
Study 29955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified blended foods (FBFs)
Number of subjects: 0
Study 29955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative commodities (sorghum and cowpea)
Number of subjects: 0
Study 29955707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Carbohydrate and Essential Amino Acid Supplement
Number of subjects: 0
Study 29955707 — intervention group
Group type: COMPARATOR
Intervention: Non-Nutritive Placebo
Number of subjects: 0
Study 29955710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Ethanol Consumption
Number of subjects: 0
Study 29955710 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29955713 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified Medium-Chain Triglycerides
Number of subjects: 0
Study 29955713 — intervention group
Group type: COMPARATOR
Intervention: Non-emulsified Medium-Chain Triglycerides
Number of subjects: 0
Study 29955720 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption intervention
Number of subjects: 0
Study 29955731 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein, High-Fiber (HP/HFb) beverage preload
Number of subjects: 50
Study 29955731 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric Lower-Protein, Lower-Fiber (LP/LFb) placebo beverage
Number of subjects: 50
Study 29955789 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 levels 60-100 nmol/l in early luteal phase
Number of subjects: 602
Study 29955789 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 levels >400 nmol/l in early luteal phase
Number of subjects: 602
Study 29955789 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 levels 150-250 nmol/l in mid-luteal phase
Number of subjects: 602
Study 29955789 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 levels >400 nmol/l in mid-luteal phase
Number of subjects: 602
Study 29955792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib 300 mg administered orally twice per day for 21 days and T-DM1 3.6 mg/kg administered intravenously once every 21 days.
Number of subjects: 57
Study 29955792 — intervention group
Group type: COMPARATOR
Intervention: T-DM1
Number of subjects: 57
Study 29955793 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy
Number of subjects: 129
Study 29955836 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine
Number of subjects: 0
Study 29955837 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous carriers for hereditary fructose intolerance (hHFI)
Number of subjects: 8
Study 29955837 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 8
Study 29955838 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher spermidine intake
Number of subjects: 829
Study 29957147 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-repetition sit-to-stand (5R-STS) test
Number of subjects: 157
Study 29957229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with HFpEF
Number of subjects: 58
Study 29957229 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 58
Study 29957715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Phase I (focused education program and implementation of treatment bundle)
Number of subjects: 1594
Study 29957715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Phase II (provision of resources to implement treatment bundle)
Number of subjects: 1594
Study 29957715 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention
Number of subjects: 1594
Study 29957715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention I
Number of subjects: 1594
Study 29957715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention II
Number of subjects: 1594
Study 29958217 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous capnography monitoring after cesarean delivery
Number of subjects: 80
Study 29958217 — intervention group
Group type: COMPARATOR
Intervention: Nurse observations of respiratory rate (RR)
Number of subjects: 80
Study 29958217 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography device usage
Number of subjects: 80
Study 29958217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 80
Study 29958223 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score of <2
Number of subjects: 449
Study 29958223 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score of ≥6
Number of subjects: 449
Study 29958223 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score of 6
Number of subjects: 449
Study 29958223 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang and pulse oximetry
Number of subjects: 449
Study 29958223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly pulse oximetry
Number of subjects: 449
Study 29958797 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy (IST) in severe AA patients
Number of subjects: 58
Study 29958797 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responding severe AA patients
Number of subjects: 58
Study 29958797 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 58
Study 29958797 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 29958815 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-embedded brief geriatric oncology assessment
Number of subjects: 44
Study 29959612 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic nipple-sparing mastectomy with immediate prosthetic breast reconstruction (RNSM with IPBR)
Number of subjects: 33
Study 29959653 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) high frequency (50 Hz)/short duration (180 s)
Number of subjects: 35
Study 29959653 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) high frequency/long duration (360 s)
Number of subjects: 35
Study 29959653 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) low frequency (30 Hz)/short duration
Number of subjects: 35
Study 29959653 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) low frequency/long duration
Number of subjects: 35
Study 29959653 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation (control)
Number of subjects: 35
Study 29959809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib (750 mg/day fasted)
Number of subjects: 20
Study 29959847 — intervention group
Group type: EXPERIMENTAL
Intervention: ThedaCare NRS
Number of subjects: 594
Study 29959847 — intervention group
Group type: COMPARATOR
Intervention: NRS 2002
Number of subjects: 594
Study 29960116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-zinc group (zinc level <71 μg/dl)
Number of subjects: 108
Study 29960116 — intervention group
Group type: COMPARATOR
Intervention: Normal-zinc group (zinc level ≥71 μg/dl)
Number of subjects: 108
Study 29960588 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) thickness measurement
Number of subjects: 140
Study 29960588 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) mass index measurement
Number of subjects: 140
Study 29960588 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial function measurement (e' and GLS)
Number of subjects: 140
Study 29960692 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 319
Study 29960692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 319
Study 29960692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and CBT
Number of subjects: 319
Study 29960692 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 319
Study 29960692 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment response
Number of subjects: 319
Study 29960692 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment type
Number of subjects: 319
Study 29960692 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 319
Study 29960701 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell ovarian transplant (ASCOT)
Number of subjects: 17
Study 29960809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian dietary patterns
Number of subjects: 664
Study 29960985 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of plasma 8-oxo-2'-dG
Number of subjects: 3766
Study 29960985 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 8-oxo-2'-dG levels
Number of subjects: 3766
Study 29960990 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF excess defined as ECW/TBW ≥0.390 or ≥0.400 depending on severity.
Number of subjects: 1741
Study 29960990 — intervention group
Group type: EXPERIMENTAL
Intervention: ECW/TBW measured using bioelectrical impedance analysis.
Number of subjects: 1741
Study 29960997 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life assessment using VSP-A and Kidscreen 10
Number of subjects: 302
Study 29960997 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's perspective on QoL
Number of subjects: 302
Study 29960997 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' perspective on QoL
Number of subjects: 302
Study 29961004 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-App (cognitive bias modification-appraisals)
Number of subjects: 80
Study 29961004 — intervention group
Group type: COMPARATOR
Intervention: Sham-training control condition (peripheral vision task)
Number of subjects: 80
Study 29961004 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-App
Number of subjects: 80
Study 29961004 — intervention group
Group type: COMPARATOR
Intervention: Sham-training control condition
Number of subjects: 80
Study 29961015 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA)
Number of subjects: 400
Study 29961015 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthesia protocol
Number of subjects: 400
Study 29961023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) using a tapered flow resistive loading device (POWERbreathe KH2, HaB International, UK), four sets of 6-10 breaths daily against an external load, adjusted to the highest tolerable load.
Number of subjects: 90
Study 29961023 — intervention group
Group type: COMPARATOR
Intervention: Sham-IMT (control group) training against a low resistance that will not be modified during the training period.
Number of subjects: 90
Study 29961023 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 90
Study 29961037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 50 Allergan Units of botulinum toxin A (BTA) resuspended in 1 mL saline + splinting
Number of subjects: 60
Study 29961037 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (1 mL) + splinting
Number of subjects: 60
Study 29961037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 50 Allergan Units of BTA + splinting
Number of subjects: 60
Study 29961039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30
Study 29961039 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (DEL)
Number of subjects: 30
Study 29961213 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (HP) gel
Number of subjects: 31
Study 29961213 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (HP) gel (control)
Number of subjects: 31
Study 29961246 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin 0.3 U/kg (high dose corticosteroids group)
Number of subjects: 60
Study 29961246 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin 0.15 U/kg (low dose corticosteroids group)
Number of subjects: 60
Study 29961246 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 29961351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study 29961351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise training)
Number of subjects: 0
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct costs per patient during follow-up
Number of subjects: 831
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost drivers associated with therapies received
Number of subjects: 831
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization/emergency costs
Number of subjects: 831
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly direct costs per patient during distant metastasis/terminal illness phase
Number of subjects: 831
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly direct costs per patient during adjuvant treatment period
Number of subjects: 831
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated mean total indirect costs per patient
Number of subjects: 831
Study 29961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual national direct cost
Number of subjects: 831
Study 29961808 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-time Exercise (ZTEx) intervention
Number of subjects: 28
Study 29961808 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participants
Number of subjects: 28
Study 29961841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert-PoC testing at birth
Number of subjects: 614
Study 29961841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert-DBS testing at birth
Number of subjects: 614
Study 29961841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert testing by week 3
Number of subjects: 614
Study 29961841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert-PoC testing at week 6
Number of subjects: 614
Study 29961841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert-PoC tests overall
Number of subjects: 614
Study 29962529 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of IV parecoxib
Number of subjects: 61
Study 29962529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29962926 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg single oral dose for 3 days, then 25 mg QD for 5 days, and 12.5 mg QD for another 3 days
Number of subjects: 3